Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
07/2012
07/05/2012WO2012019184A3 Compositions and methods for detecting, diagnosing, and treating cancer
07/05/2012WO2012018949A3 Compositions and methods for the treatment of cancer
07/05/2012WO2012011741A9 Novel fusarisetin compounds, and use thereof
07/05/2012WO2012008762A3 Composition comprising extracts or fractions of specific plants, use thereof and process for preparing the extracts
07/05/2012US20120172591 Inhibitors of human phosphatidylinositol 3-kinase delta
07/05/2012US20120172449 Polyamine transport inhibitors as novel therapeutics
07/05/2012US20120172427 (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability
07/05/2012US20120172424 Chroman derivatives, medicaments and use in therapy
07/05/2012US20120172421 2, 6 xylidine derivatives for the treatment of pain
07/05/2012US20120172416 Method for the preparation of micro-rna and its therapeutic application
07/05/2012US20120172406 Androgen receptor antagonists and uses thereof
07/05/2012US20120172402 Induction of alpha helix conformations in proteins and peptides
07/05/2012US20120172399 Compounds as hypoxia mimetics, and composiitons and uses thereof
07/05/2012US20120172397 HEXAHYDROCYCLOPENTA[f]INDAZOLE 5-YL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
07/05/2012US20120172389 Treatment of fibrosing disorders
07/05/2012US20120172382 Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
07/05/2012US20120172380 Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agent
07/05/2012US20120172379 4 substituted pyrazolopyrimidines
07/05/2012US20120172374 Novel tubulin inhibitors and methods of using the same
07/05/2012US20120172371 Fluoroquinolone derivatives or sulfonamide moiety-containing compounds as inhibitors of tyrosyl-dnaphosphodiesterase (tdp1)
07/05/2012US20120172370 Preparation of crystalline forms of dihydropyrazolopyrimidinone
07/05/2012US20120172364 Rate-controlled particles
07/05/2012US20120172361 Triazine derivatives and their therapeutical applications
07/05/2012US20120172360 Novel 1h-pyrimidin-2-one derivatives, preparation thereof and pharmaceutical use thereof as inhibitors of akt (pkb) phosphorylation
07/05/2012US20120172359 Oxazine Derivatives and their Use in the Treatment of Neurological Disorders
07/05/2012US20120172352 Pyrazoline dione derivatives as nadph oxidase inhibitors
07/05/2012US20120172349 Therapeutic compounds and compositions
07/05/2012US20120172345 Heteroaryls and uses thereof
07/05/2012US20120172339 Angiogenic resorcinol derivatives
07/05/2012US20120172337 Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses
07/05/2012US20120172333 Pyrrolo-pyridine derivatives as activators of ampk
07/05/2012US20120172315 Peptides Used for Treating Cancers and, in Particular, Chronic Lymphoid Leukaemia
07/05/2012US20120172314 Klotho Protein and Related Compounds for the Treatment and Diagnosis of Cancer
07/05/2012US20120172313 Treatment of proliferative diseases
07/05/2012US20120172312 Muc-1 cytoplasmic domain peptides as inhibitors of cancer
07/05/2012US20120172311 Peptidomimetic macrocycles
07/05/2012US20120172310 Soluble Guanylyl Cyclase a1 and a-8r Peptide as Diagnostic Markers of and Therapeutic Targets for Prostate Cancer
07/05/2012US20120172300 Remodeling and glycopegylation of fibroblast growth factor (fgf)
07/05/2012US20120172292 Method for protection of antimicrobial and anticancer drugs from inactivation by nitric oxide
07/05/2012US20120172286 Therapeutic use for alpha1 proteinase inhibitor in hematopoiesis
07/05/2012US20120172285 Methods and compositions for specific modulation of mcl-1
07/05/2012US20120171765 Factor VII or VIIa - Like Molecules
07/05/2012US20120171306 Therapeutic treatment of cancer and dysplasia of the cervix or vagina using estrogen antagonists
07/05/2012US20120171305 Response Prediction in Cancer Treatment Involving p53 Adapted Cancer Therapy
07/05/2012US20120171304 Stabilized Aptamers To Platelet Derived Growth Factor And Their Use As Oncology Therapeutics
07/05/2012US20120171302 Compositions and methods for inhibiting redox-sensitive gtpases
07/05/2012US20120171292 Luminescent porous silicon nanoparticles for targeted delivery and immunization
07/05/2012US20120171289 Delivery systems for bioactive agents
07/05/2012US20120171284 Celecoxib compositions
07/05/2012US20120171283 Liposomes Useful for Drug Delivery
07/05/2012US20120171280 Method of making liposomes, liposome compositions made by the methods, and methods of using the same
07/05/2012US20120171279 Strongly bound base-modified oligonucleotides
07/05/2012US20120171275 Local administration of gallium compositions to treat pain
07/05/2012US20120171261 Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles and their use for diagnostics and therapy
07/05/2012US20120171246 Immunization to reduce neurotoxicity during treatment with cytolytic viruses
07/05/2012US20120171244 Mucosal boosting following parenteral priming
07/05/2012US20120171240 Immunostimulatory compositions and methods
07/05/2012US20120171232 In vivo efficacy of ny-eso-1 plus adjuvant
07/05/2012US20120171229 Synthetic nanocarriers with reactive groups that release biologically active agents
07/05/2012US20120171228 Anti-cancer regimen
07/05/2012US20120171227 Pro-drug complexes and related methods of use
07/05/2012US20120171226 Antibodies to high molecular weight melanoma associated antigen
07/05/2012US20120171225 Diagnostic Method for Predicting the Risk of Cancer Recurrence Based on Histone Macroh2A Isoforms
07/05/2012US20120171222 Methods and compositions involving nucleotide repeat disorders
07/05/2012US20120171220 Further use of protein kinase n beta
07/05/2012US20120171219 Use of pkc-zeta as a breast cancer tumorigenic biomarker as well as a target for treatment of breast cancer
07/05/2012US20120171216 Palmitated monoclonal antibody
07/05/2012US20120171213 Method of treating tumors
07/05/2012US20120171210 Methods and compositions for inhibiting c-met dimerization and activation
07/05/2012US20120171207 Depleting immunosuppressive monocytes within a mammal
07/05/2012US20120171205 Galectin-Immunoglobulin Chimeric Molecules
07/05/2012US20120171203 Activin receptor-like kinase-1 compositions and methods of use
07/05/2012US20120171202 Rage Fusion Proteins And Methods Of Use
07/05/2012US20120171201 Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
07/05/2012US20120171200 Antibodies With Immune Effector Activity And That Internalize In Folate Receptor Alpha-Positive Cells
07/05/2012US20120171199 Tricyclic pi3k inhibitor compounds and methods of use
07/05/2012US20120171192 Methods and materials for modulating deubiquitinases and ubiquitinated polypeptides
07/05/2012US20120171181 Compositions and minimally invasive methods for treating cancer
07/05/2012US20120171170 Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
07/05/2012US20120171159 Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof
07/05/2012US20120171153 Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
07/05/2012US20120171119 Pegylated fluorobenzamide analogues, their synthesis and use in diagnostic imaging
07/05/2012US20120171118 Treatment of meningeal and neural diseases
07/05/2012US20120171116 Arginase Inhibitors and Methods of Use Thereof
07/05/2012CA2823401A1 Therapeutic compounds and compositions
07/05/2012CA2823138A1 Sirna for inhibition of hif1a expression and anticancer composition containing the same
07/05/2012CA2822939A1 A cross-linking polypeptide that induces apoptosis
07/05/2012CA2822938A1 A polypeptide that binds aberrant cells and induces apoptosis
07/05/2012CA2822207A1 Oxidosqualene cyclase as a protein target for anticancer therapeutics
07/05/2012CA2822114A1 Sirna against cbl-b and optionally il-2 and il-12 for use in the treatment of cancer
07/05/2012CA2822061A1 Anti-cd38 antibodies
07/05/2012CA2820087A1 Compositions and methods of using crystalline forms of wortmannin analogs
07/05/2012CA2816041A1 In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
07/04/2012EP2471918A1 Screening method
07/04/2012EP2471814A1 Anti-vegf monoclonal antibody and pharmaceutical composition comprising said antibody
07/04/2012EP2471793A1 Fused heterocyclic ring derivative and use thereof
07/04/2012EP2471791A1 Fused heterocyclic ring derivative and use thereof
07/04/2012EP2471790A1 Fused heterocyclic ring derivative and use thereof
07/04/2012EP2471789A1 Fused heterocyclic ring derivative and use thereof
07/04/2012EP2471787A1 New compounds
1 ... 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 ... 2211